On the monthly chart, you can see a rather stable stock price in May and a dramatic spike in the price from $2.28 to $3.1 from June 4 to June 7. However, if you look at the dynamics for the last six months, you’ll notice a fairly inactive chart; what should you expect?
In the United States, the corporation wants to open at least 13 clinical sites for Alzheimer’s disease research and 18 clinical centers for head and neck cancer. In addition, the company expects to activate at least 13 Alzheimer’s research sites and 18 HNSCC sites in the United States.
The study will include at least 40 patients with critical performance outcomes such as cognitive function measures and brain imaging and will validate the idea of Alzheimer’s disease. The Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association provided funding for this research.
Forward-looking statements are subject to a number of risks and uncertainties, which could cause the Company’s research and preclinical development programs, clinical development programs, future results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. As a result, investors should tread carefully while investing in this company.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.